Skip to main
TIL

Instil Bio (TIL) Stock Forecast & Price Target

Instil Bio (TIL) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Instil Bio Inc focuses on developing innovative cell therapies for cancer treatment, with a promising pipeline that includes ITIL-306, which targets tumor-associated antigens across various solid tumors. The validation of the PD-(L)1 × VEGF activity, as seen in the recent reports, highlights the potential synergies within the therapeutic class and suggests a positive trajectory for the application of Instil Bio's TIL therapies. Furthermore, the potential for the CoStAR platform to expand into additional indications without being factored into current valuations indicates significant upside opportunities for the company's stock.

Bears say

Instil Bio's stock outlook is negatively impacted by the discontinuation of AXN-2510, which was deemed a core value driver, leading to a full thesis reset that emphasizes cash constraints. There are significant risks associated with the company’s clinical pipeline, including potential delays in advancing candidates and an inability to produce favorable clinical data, particularly concerning AXN-2510 in NSCLC and SCLC. Additionally, the termination of the collaboration agreement with ImmuneOnco Biopharmaceuticals raises further concerns about strategic direction, prompting a view of the stock as lacking immediate momentum and being valued close to cash levels.

Instil Bio (TIL) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Instil Bio (TIL) Forecast

Analysts have given Instil Bio (TIL) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Instil Bio (TIL) has a Strong Buy consensus rating as of Jan 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Instil Bio (TIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.